Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Biomark Diagnostics

Biomark Diagnostics
2007 FOUNDED
PUBLIC STATUS
BUX STOCK SYMBOL
$0.07 SHARE PRICE (As of Wednesday Closing)
Description

Developer of advanced stage diagnostic technologies intended to increase the accuracy of cancer diagnostics. The company's advanced stage diagnostic technologies consists of screening for the acetylated form of a drug (Amantadine) given to patients prior to measurement via LC MS in body fluids, this acetylation is performed by the enzyme, spermine/spermidine n-acetyl transferase (SSAT), enabling medical institutions to gain universal access to effective cancer diagnostic tools.

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Healthcare Technology Systems
Stock Exchange
CNQ
Primary Office
  • 165 - 10551 Shellbridge Way
  • Richmond, British Columbia V6X 2W8
  • Canada

+1 (604) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Biomark Diagnostics’s full profile, request a free trial.

Biomark Diagnostics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.05 - $0.13 $4.91M $0.08 25.6K 62.8M

Biomark Diagnostics Financials Summary

In Thousands,
USD
TTM
31-Dec-2017
FY 2017
31-Mar-2017
FY 2016
31-Mar-2016
FY 2015
31-Mar-2015
Enterprise Value 4,675 3,865 5,948 14,998
EBITDA (629) (545) (1,068) (2,525)
Net Income (629) (545) (1,068) (2,525)
Total Assets 117 30 26 182
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biomark Diagnostics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Biomark Diagnostics‘s full profile, request access.

Request full access to PitchBook

Biomark Diagnostics Executive Team (4)

Name Title Board
Seat
Contact
Info
Rashid Ahmed Founder & Chief Executive Officer
Thomas Malcolm President & Chief Scientific Officer
Abbey Abdiye Chief Financial Officer
Brian Cheng Chief Technical Officer